US$ 25.80
switching between glp-1 agonists Outcomes in RA-Experienced Patients to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study | Diabetes Therapy Switching GLP-1 Agonists for MAXIMUM
Description
H.RipaR

Amongst SGLT2-I, canagliflozin specifically has raised concerns about risk of bone fracture, although it is unclear whether an association exists with other SGLT2-I

Contact an Edwardsville premises liability lawyer from TorHoerman Law today for a free, no-obligation case consultation

EDIT: Added after original publication for release to free subscribers

Juji A, Godina C, Belting M, Melander O, Juul Holst J, Ahlqvist E, et al
